Now showing items 1-20 of 20

    • Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment 

      Herter-Sprie, Grit S.; Greulich, Heidi E.; Wong, Kwok-Kin (Frontiers Media S.A., 2013)
      Despite the ongoing “war on cancer,” cancer remains one of the major causes of human morbidity and mortality. A new paradigm of targeted therapies holds the most promise for the future, making identification of tumor-specific ...
    • Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors 

      Akbay, E; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, Camilla Laulund; Mikse, O. R.; Cherniack, Andrew David; Beauchamp, Ellen Monica; Pugh, T; Wilkerson, M. D.; Fecci, P; Butaney, M.; Reibel, J. B.; Soucheray, M.; Cohoon, T. J.; Janne, Pasi Antero; Meyerson, Matthew Langer; Hayes, D. N.; Shapiro, Geoffrey Ira; Shimamura, T; Sholl, Lynette Marie; Rodig, Scott J.; Freeman, Gordon James; Hammerman, Peter Seth; Dranoff, G; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2013)
      The success in lung cancer therapy with Programmed Death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between Epidermal Growth Factor Receptor ...
    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints 

      Koyama, Shohei; Akbay, Esra A.; Li, Yvonne Y.; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Richards, William G.; Gandhi, Leena; Redig, Amanda J.; Rodig, Scott J.; Asahina, Hajime; Jones, Robert E.; Kulkarni, Meghana M.; Kuraguchi, Mari; Palakurthi, Sangeetha; Fecci, Peter E.; Johnson, Bruce E.; Janne, Pasi A.; Engelman, Jeffrey A.; Gangadharan, Sidharta P.; Costa, Daniel B.; Freeman, Gordon J.; Bueno, Raphael; Hodi, F. Stephen; Dranoff, Glenn; Wong, Kwok-Kin; Hammerman, Peter S. (Nature Publishing Group, 2016)
      Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. ...
    • CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer 

      Li, Chong; Liu, Shengwu; Yan, Ruping; Han, Ning; Wong, Kwok-Kin; Li, Lei (Ivyspring International Publisher, 2017)
      Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling ...
    • Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor suppressor activities 

      Kagawa, Shingo; Natsuizaka, Mitsuteru; Whelan, Kelly A.; Facompre, Nicole; Naganuma, Seiji; Ohashi, Shinya; Kinugasa, Hideaki; Egloff, Ann Marie; Basu, Devraj; Gimotty, Phyllis A.; Klein-Szanto, Andres J; Bass, Adam; Wong, Kwok-Kin; Diehl, J. Alan; Rustgi, Anil K.; Nakagawa, Hiroshi (2014)
      Notch activity regulates tumor biology in a context-dependent and complex manner. Notch may act as an oncogene or a tumor suppressor gene even within the same tumor type. Recently, Notch signaling has been implicated in ...
    • Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas 

      Sholl, Lynette Marie; Weremowicz, Stanislawa; Gray, Stacy; Wong, Kwok-Kin; Chirieac, Lucian Radu; Lindeman, Neal I.; Hornick, Jason L. (Elsevier BV, 2013)
      INTRODUCTION ALK gene rearrangements occur in ~5% of lung adenocarcinomas (ACA), leading to ALK overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the gold standard ...
    • Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment 

      Lizotte, Patrick H.; Jones, Robert E.; Keogh, Lauren; Ivanova, Elena; Liu, Hongye; Awad, Mark M.; Hammerman, Peter S.; Gill, Ritu R.; Richards, William G.; Barbie, David A.; Bass, Adam J.; Bueno, Raphael; English, Jessie M.; Bittinger, Mark; Wong, Kwok-Kin (Nature Publishing Group, 2016)
      With the emergence of checkpoint blockade and other immunotherapeutic drugs, and the growing adoption of smaller, more flexible adaptive clinical trial designs, there is an unmet need to develop diagnostics that can rapidly ...
    • Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models 

      Herter-Sprie, Grit S.; Korideck, Houari; Christensen, Camilla L.; Herter, Jan M.; Rhee, Kevin; Berbeco, Ross I.; Bennett, David G.; Akbay, Esra A.; Kozono, David; Mak, Raymond H.; Makrigiorgos, G. Mike; Kimmelman, Alec C.; Wong, Kwok-Kin (2014)
      Close resemblance of murine and human trials is essential to achieve the best predictive value of animal-based translational cancer research. Kras-driven genetically engineered mouse models of non-small cell lung cancer ...
    • The impact of the MYB-NFIB fusion proto-oncogene in vivo 

      Mikse, Oliver R.; Tchaicha, Jeremy H.; Akbay, Esra A.; Chen, Liang; Bronson, Roderick T.; Hammerman, Peter S.; Wong, Kwok-Kin (Impact Journals LLC, 2016)
      Recurrent fusion of the v-myb avian myelobastosis viral oncogene homolog (MYB) and nuclear factor I/B (NFIB) generates the MYB-NFIB transcription factor, which has been detected in a high percentage of individuals with ...
    • Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC 

      Tchaicha, J. H.; Akbay, E; Altabef, A.; Mikse, O. R.; Kikuchi, E.; Rhee, K.; Liao, R; Bronson, Roderick Terry; Sholl, Lynette Marie; Meyerson, Matthew Langer; Hammerman, Peter Seth; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2014)
      Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified in patients ...
    • The LKB1 Tumor Suppressor as a Biomarker in Mouse and Human Tissues 

      Nakada, Yuji; Stewart, Thomas G.; Peña, Christopher G.; Zhang, Song; Zhao, Ni; Bardeesy, Nabeel; Sharpless, Norman E.; Wong, Kwok-Kin; Hayes, D. Neil; Castrillon, Diego H. (Public Library of Science, 2013)
      Germline mutations in the LKB1 gene (also known as STK11) cause the Peutz-Jeghers Syndrome, and somatic loss of LKB1 has emerged as causal event in a wide range of human malignancies, including melanoma, lung cancer, and ...
    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...
    • Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer 

      Tan, Xiaohong; Carretero, Julian; Chen, Zhao; Zhang, Jishuai; Wang, Yanxiao; Chen, Jicheng; Li, Xiubin; Ye, Hui; Tang, Chuanhao; Cheng, Xuan; Hou, Ning; Yang, Xiao; Wong, Kwok-Kin (Public Library of Science, 2013)
      Interleukin-6 (IL-6) is involved in lung cancer tumorigenesis, tumor progression, metastasis, and drug resistance. Previous studies show that blockade of IL-6 signaling can inhibit tumor growth and increase drug sensitivity ...
    • MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells 

      Kharbanda, Akriti; Rajabi, Hasan; Jin, Caining; Alam, Maroof; Wong, Kwok-Kin; Kufe, Donald (Impact Journals LLC, 2014)
      Non-small cell lung cancers (NSCLCs) that harbor an oncogenic KRAS mutation are often associated with resistance to targeted therapies. The MUC1-C transmembrane protein is aberrantly overexpressed in NSCLCs and confers a ...
    • Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer 

      Mak, Raymond Heungwing; Hermann, Gretchen; Lewis, John H.; Aerts, Hugo J.W.L.; Baldini, Elizabeth Healey; Chen, Aileen Betty; Colson, Yolonda L.; Hacker, Fred L.; Kozono, David Eiichi; Wee, Jon O.; Chen, Yu-Hui; Catalano, Paul J.; Wong, Kwok-Kin; Sher, David J. (Elsevier BV, 2015)
      BACKGROUND: We analyzed outcomes after lung stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung-carcinoma (NSCLC) by histology and KRAS genotype. PATIENTS AND METHODS: We included 75 patients with 79 ...
    • Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors 

      Ercan, Dalia; Xu, Chunxiao; Yanagita, Masahiko; Monast, Calixte S.; Pratilas, Christine A.; Montero, Joan; Butaney, Mohit; Shimamura, Takeshi; Sholl, Lynette Marie; Ivanova, Elena; Tadi, Madhavi; Rogers, Andrew; Repellin, Claire; Capelletti, Marzia; Maertens, Ophelia; Goetz, Eva Marie; Letai, Anthony George; Garraway, Levi Alexander; Lazzara, Matthew J.; Rosen, Neal; Gray, Nathanael Schiander; Wong, Kwok-Kin; Janne, Pasi Antero (American Association for Cancer Research (AACR), 2012)
      The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by ...
    • RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS 

      Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao; Sattler, Martin; Dori, Martina; Agnelli, Luca; Hacken, Elisa ten; Bertilaccio, Maria Teresa; Antonini, Elena; Neri, Antonino; Ponzoni, Maurilio; Marcatti, Magda; Richardson, Paul G.; Carrasco, Ruben; Kimmelman, Alec C.; Wong, Kwok-Kin; Caligaris-Cappio, Federico; Blandino, Giovanni; Kuehl, W. Michael; Anderson, Kenneth C.; Tonon, Giovanni (2014)
      Oncogene–induced DNA damage elicits genomic instability in epithelial cancer cells, but apoptosis is blocked through inactivation of the tumor suppressor p53. In hematological cancers, the relevance of ongoing DNA damage ...
    • SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas 

      Bass, Adam Joel; Watanabe, Hideo; Mermel, Craig; Yu, Soyoung; Perner, Sven; Verhaak, Roel; Kim, So Jeong; Wardwell, Leslie; Tamayo, Pablo; Gat-Viks, Irit; Ramos, Alex H; Woo, Michele S; Weir, Barbara Ann; Getz, Gad A; Beroukhim, Rameen; O, Michael; Dutt, Amit; Rozenblatt-Rosen, Orit; Dziunycz, Piotr; Komisarof, Justin; Chirieac, Lucian Radu; LaFargue, Christopher J; Scheble, Veit; Wilbertz, Theresia; Ma, Changqing; Rao, Shilpa; Nakagawa, Hiroshi; Stairs, Douglas B; Lin, Lin; Giordano, Thomas J; Wagner, Patrick; Minna, John D; Gazdar, Adi F; Zhu, Chang Qi; Brose, Marcia S; Cecconello, Ivan; Jr, Ulysses Ribeiro; Marie, Suely K; Dahl, Olav; Shivdasani, Ramesh Arjun; Tsao, Ming-Sound; Rubin, Mark A; Wong, Kwok-Kin; Regev, Aviv; Hahn, William Chun; Beer, David G; Rustgi, Anil K; Meyerson, Matthew Langer (Springer Nature, 2009)
      Lineage survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development.1,2 Here we show that a peak of genomic amplification on ...
    • Temporal Dissection of K-ras\(^{G12D}\) Mutant In Vitro and In Vivo Using a Regulatable K-ras\(^{G12D}\) Mouse Allele 

      Wang, Zuoyun; Feng, Yan; Bardessy, Nabeel; Wong, Kwok-Kin; Liu, Xin-Yuan; Ji, Hongbin (Public Library of Science, 2012)
      Animal models which allow the temporal regulation of gene activities are valuable for dissecting gene function in tumorigenesis. Here we have constructed a conditional inducible estrogen receptor-K-ras\(^{G12D}\) ...
    • Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma 

      Han, Xiangkun; Li, Fuming; Fang, Zhaoyuan; Gao, Yijun; Li, Fei; Fang, Rong; Yao, Shun; Sun, Yihua; Li, Li; Zhang, Wenjing; Ma, Huimin; Xiao, Qian; Ge, Gaoxiang; Fang, Jing; Wang, Hongda; Zhang, Lei; Wong, Kwok-kin; Chen, Haiquan; Hou, Yingyong; Ji, Hongbin (Nature Pub. Group, 2014)
      Lineage transition in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of non-small cell lung cancer, as implicated by clinical observation of mixed ADC and SCC pathologies in adenosquamous cell carcinoma, remains a ...